Beskrivelse
Krav
IPC-klasse
Fullmektig i Norge:
Fullmektig i EP:
2012.07.12, US 201261671044 P
ANDREW C MCCREARY ET AL: "The thyrotrophin-releasing hormone analogue MK771 induces tic-like behaviours: the effects of dopamine D1 and D2 receptor antagonists", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 369, no. 1, 1 March 1999 (1999-03-01) , pages 1-9, XP055221494, NL ISSN: 0014-2999, DOI: 10.1016/S0014-2999(99)00039-4 (B8)
ARNE ASTRUP ET AL: "'Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects", OBESITY RESEARCH, BATON ROUGE, LA, US, vol. 15, no. 7, 7 July 2007 (2007-07-07), pages 1717-1731, XP008156118, ISSN: 1071-7323, DOI: 10.1002/HBM.22021 (B8)
Anonymous: "Clinica Trials Archive - History of Changes for Study: NCT01244633", , 8 May 2012 (2012-05-08), XP55738348, Retrieved from the Internet: URL:https://www.clinicaltrials.gov/ct2/his tory/NCT01244633?V_5=View#StudyPageTop [retrieved on 2020-10-09] (B8)
DATABASE PUBMED [Online] 25 October 2006 XP055184772 Retrieved from NCBI Database accession no. 10591286 & ROMACH MK ET AL.: 'Attenuation of the euphoric effects of cocaine by the dopamine DI/D5 antagonist ecopipam (SCH 39166).' ARCH GEN PSYCHIATRY vol. 56, no. 12, 1999, pages 1101 - 1106 (B8)
DURSUN S M ET AL: "SIMILARITIES IN THE PHARMACOLOGY OF SPONTANEOUS AND DOI-INDUCED HEAD-SHAKES SUGGEST 5HT2A RECEPTORS ARE ACTIVE UNDER PHYSIOLOGICAL CONDITIONS", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 128, no. 2, 1 January 1996 (1996-01-01), pages 198-205, XP001059606, ISSN: 0033-3158, DOI: 10.1007/S002130050125 (B8)
Jang-Woo Shin ET AL: "Interpretation of Animal Dose and Human Equivalent Dose for Drug Development", The Journal of Korean Oriental Medicine, 1 May 2010 (2010-05-01), pages 1-7, XP55315075, Retrieved from the Internet: URL:http://jkom.org/upload/31-3 01 [01-07].pdf [retrieved on 2016-10-31] (B8)
WO-A1-96/13257 (B8)
QIANG L ET AL: "Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 3, 1 February 2010 (2010-02-01), pages 836-840, XP026861816, ISSN: 0960-894X [retrieved on 2010-01-04] (B8)
REAGAN-SHAW SHANNON ET AL: "Dose translation from animal to human studies revisited.", FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY MAR 2008, vol. 22, no. 3, March 2008 (2008-03), pages 659-661, ISSN: 1530-6860 (B8)
ROGER KURLAN, M.D.: 'Tourette's Syndrome.' THE NEW ENGLAND JOURNAL OF MEDICINE vol. 363, 2010, pages 2332 - 2338, XP008176095 Retrieved from the Internet: <URL:http:JJwww.nejm.org/doi/full/ 10.1056lnejmcp 1007805> (B8)
WO-A1-2011/057199 (B8)
WO-A1-2012/033874 (B8)
Lynn Dunlap: "TSA, Psyadon to collaborate on drug trial", , May 2011 (2011-05), Retrieved from the Internet: URL:https://missouritsa.org/2011/05/12/tsa -psyadon-to-collaborate-on-drug-trial/ [retrieved on 2017-04-11] (B8)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP2872145)
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP2872145)
|
Innkommende, AR492038161
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 12. avg. år (EP) | 2024.07.09 | 5010 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 11. avg. år (EP) | 2023.07.12 | 3500 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 10. avg. år (EP) | 2022.07.08 | 3200 | CPA GLOBAL LIMITED | Betalt og godkjent |
32207915 expand_more expand_less | 2022.06.02 | 5580 | Budde Schou A/S | Betalt |
Gebyr ved bruk av MasterCard-kort
80 = 80 X 1
Valideringsgebyr EP-patent
5500 = 1 X 5500
|